WO1999022735A1 - Agonistes de la somatostatine - Google Patents
Agonistes de la somatostatine Download PDFInfo
- Publication number
- WO1999022735A1 WO1999022735A1 PCT/US1998/022917 US9822917W WO9922735A1 WO 1999022735 A1 WO1999022735 A1 WO 1999022735A1 US 9822917 W US9822917 W US 9822917W WO 9922735 A1 WO9922735 A1 WO 9922735A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- aryl
- group
- heteroaryl
- mammal
- Prior art date
Links
- 0 CC(C)(*)NC Chemical compound CC(C)(*)NC 0.000 description 10
- BTMDPAUQQWYDRJ-UHFFFAOYSA-N C(c1ccccc1)Oc1cccc2c1CC=C2 Chemical compound C(c1ccccc1)Oc1cccc2c1CC=C2 BTMDPAUQQWYDRJ-UHFFFAOYSA-N 0.000 description 1
- ILXWORJMVDQZKE-UHFFFAOYSA-N CC(C)(C)OC(NCc1cccc(CN)n1)=O Chemical compound CC(C)(C)OC(NCc1cccc(CN)n1)=O ILXWORJMVDQZKE-UHFFFAOYSA-N 0.000 description 1
- OAMPTALTBHXPGL-AEFFLSMTSA-N CC(C)(C)OC([C@H](CCCCI)NC([C@@H](Cc1c[nH]c2ccccc12)N)=O)=O Chemical compound CC(C)(C)OC([C@H](CCCCI)NC([C@@H](Cc1c[nH]c2ccccc12)N)=O)=O OAMPTALTBHXPGL-AEFFLSMTSA-N 0.000 description 1
- DGVLYTBXGIQZIA-XZWHSSHBSA-N CC(C)(C)OC([C@H](CCCCN)NC([C@@H](Cc1c[nH]c2c1cccc2)NC(N(CC1)CCC11c2ccccc2CC1)=O)=O)=O Chemical compound CC(C)(C)OC([C@H](CCCCN)NC([C@@H](Cc1c[nH]c2c1cccc2)NC(N(CC1)CCC11c2ccccc2CC1)=O)=O)=O DGVLYTBXGIQZIA-XZWHSSHBSA-N 0.000 description 1
- BZJSWVSSTYSNER-ZBFHGGJFSA-N COC([C@H](CCCCI)NC([C@@H](Cc1c[nH]c2ccccc12)N)=O)=O Chemical compound COC([C@H](CCCCI)NC([C@@H](Cc1c[nH]c2ccccc12)N)=O)=O BZJSWVSSTYSNER-ZBFHGGJFSA-N 0.000 description 1
- OBUHMFMNVKAFAG-FSGGQHMVSA-N C[C@H](CSCCN(C)C)NC([C@@H]([C@@H](C)c1c[nH]c2c1cccc2)NC(N(CC1)CCC11c2ccccc2CC1)=O)=O Chemical compound C[C@H](CSCCN(C)C)NC([C@@H]([C@@H](C)c1c[nH]c2c1cccc2)NC(N(CC1)CCC11c2ccccc2CC1)=O)=O OBUHMFMNVKAFAG-FSGGQHMVSA-N 0.000 description 1
- UZQDPQXWELWGPO-RZIGYZOXSA-N C[C@H](CSCCN)NC([C@@H]([C@@H](C)c1c[nH]c2c1cccc2)NC(N(CC1)CCC1(CC1)c2c1cccc2)=O)=O Chemical compound C[C@H](CSCCN)NC([C@@H]([C@@H](C)c1c[nH]c2c1cccc2)NC(N(CC1)CCC1(CC1)c2c1cccc2)=O)=O UZQDPQXWELWGPO-RZIGYZOXSA-N 0.000 description 1
- ZIFFQQOOSNBWNN-LOLKONATSA-N C[C@H]([C@H](C(N1[C@@H](CSCCN)CCC1)=O)NC(N(CC1)CCC11c2ccccc2CC1)=O)c1c[nH]c2c1cccc2 Chemical compound C[C@H]([C@H](C(N1[C@@H](CSCCN)CCC1)=O)NC(N(CC1)CCC11c2ccccc2CC1)=O)c1c[nH]c2c1cccc2 ZIFFQQOOSNBWNN-LOLKONATSA-N 0.000 description 1
- RMLWYWSYCXQVPA-RJSONGRPSA-N C[C@H]([C@H](C(N[C@@H](CCCCN)C(OC(C)(C)C)=O)=O)NC(N(CC1)CCC1(CC1)c2c1cccc2)=O)c1c[nH]c2ccccc12 Chemical compound C[C@H]([C@H](C(N[C@@H](CCCCN)C(OC(C)(C)C)=O)=O)NC(N(CC1)CCC1(CC1)c2c1cccc2)=O)c1c[nH]c2ccccc12 RMLWYWSYCXQVPA-RJSONGRPSA-N 0.000 description 1
- PNRCDWIVOQPNGF-UHFFFAOYSA-N [O-][N+](c1c(C=CC23CCNCC2)c3ccc1)=O Chemical compound [O-][N+](c1c(C=CC23CCNCC2)c3ccc1)=O PNRCDWIVOQPNGF-UHFFFAOYSA-N 0.000 description 1
- WJCXYHDSDFEAJL-UHFFFAOYSA-N [O-][N+](c1cc(C2(CCNCC2)C=C2)c2cc1)=O Chemical compound [O-][N+](c1cc(C2(CCNCC2)C=C2)c2cc1)=O WJCXYHDSDFEAJL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des composés agonistes de la somatostatine présentant un fort potentiel de haute sélectivité vis-à-vis du sous-type 2 du récepteur. Ces composés présentent un meilleur coefficient thérapeutique pour le traitement du diabète, du cancer, de l'acromégalie, et de la rétinopathie. Nombre de ces composés sont aussi oralement actifs. L'invention concerne donc, non seulement ces composés, mais également les stéréoïsomères spécifiques préférés des agonistes de la somatostatine, et aussi les procédés d'élaboration de tels composés. L'invention concerne enfin des procédés et des compositions utilisant ces composés comme principe actif. D'autres objets de l'invention sont aisément identifiables à la lecture du corps de l'invention.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU12854/99A AU1285499A (en) | 1997-10-30 | 1998-10-28 | Somatostatin agonists |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6442297P | 1997-10-30 | 1997-10-30 | |
US60/064,422 | 1997-10-30 | ||
GB9806697.0 | 1998-03-27 | ||
GBGB9806697.0A GB9806697D0 (en) | 1998-03-27 | 1998-03-27 | Somatostatin agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999022735A1 true WO1999022735A1 (fr) | 1999-05-14 |
Family
ID=26313387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/022917 WO1999022735A1 (fr) | 1997-10-30 | 1998-10-28 | Agonistes de la somatostatine |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU1285499A (fr) |
WO (1) | WO1999022735A1 (fr) |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1086947A1 (fr) * | 1999-09-01 | 2001-03-28 | Pfizer Products Inc. | Antagonistes et agonistes de la somatostatin, qui agissent sur le recepteur SST subtype 2 |
FR2802206A1 (fr) * | 1999-12-14 | 2001-06-15 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
US6316414B1 (en) | 2000-07-31 | 2001-11-13 | Dabur Research Foundation | Somatostatin analogs for the treatment of cancer |
US6495589B2 (en) | 2000-04-28 | 2002-12-17 | Pfizer Inc. | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor |
JP2003504369A (ja) * | 1999-07-13 | 2003-02-04 | メルク エンド カムパニー インコーポレーテッド | アミドスピロピペリジン類による成長ホルモン放出の促進 |
US6696418B1 (en) | 1999-09-01 | 2004-02-24 | Pfizer Inc. | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor |
US6720330B2 (en) | 2000-11-17 | 2004-04-13 | Pfizer Inc. | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor |
EP1415986A1 (fr) * | 2001-08-07 | 2004-05-06 | Banyu Pharmaceutical Co., Ltd. | Composes spiro |
WO2005041962A1 (fr) | 2003-10-31 | 2005-05-12 | Takeda Pharmaceutical Company Limited | Preparation solide comprenant un sensibilisateur a l'insuline, un secretagogue d'insuline et un ester d'acide gras de polyoxyethylene sorbitan |
JP2006519200A (ja) * | 2003-02-27 | 2006-08-24 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | シクロアルキル置換アルカン酸誘導体、その製造方法、及び医薬としてのその使用 |
WO2006118320A1 (fr) | 2005-04-28 | 2006-11-09 | Takeda Pharmaceutical Company Limited | Composé de thiénopyrimidone |
WO2006132440A1 (fr) | 2005-06-09 | 2006-12-14 | Takeda Pharmaceutical Company Limited | Preparation solide |
WO2007028135A2 (fr) | 2005-09-01 | 2007-03-08 | Takeda Pharmaceutical Company Limited | Composes a base d'imidazopyridine |
US7189856B2 (en) | 2001-12-28 | 2007-03-13 | Gideon Shapiro | Non-peptide somatostatin receptor ligands |
WO2007055418A1 (fr) | 2005-11-10 | 2007-05-18 | Banyu Pharmaceutical Co., Ltd. | Derive spiro aza-substitue |
WO2007074884A1 (fr) | 2005-12-28 | 2007-07-05 | Takeda Pharmaceutical Company Limited | Agent thérapeutique pour traiter le diabète |
WO2008016131A1 (fr) | 2006-08-04 | 2008-02-07 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique à cycles fusionnés |
WO2008136428A1 (fr) | 2007-04-27 | 2008-11-13 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique à cinq chaînons à teneur en azote |
WO2008143262A1 (fr) | 2007-05-21 | 2008-11-27 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique et son utilisation |
WO2009008487A1 (fr) | 2007-07-12 | 2009-01-15 | Takeda Pharmaceutical Company Limited | Préparation enrobée |
WO2009123316A1 (fr) | 2008-04-04 | 2009-10-08 | 武田薬品工業株式会社 | Dérivé hétérocyclique et son utilisation |
WO2009128481A1 (fr) | 2008-04-16 | 2009-10-22 | 武田薬品工業株式会社 | Composé hétérocyclique azoté à cinq chaînons |
WO2010016552A1 (fr) | 2008-08-07 | 2010-02-11 | 武田薬品工業株式会社 | Agent thérapeutique pour le syndrome du côlon irritable |
EP2161037A2 (fr) | 2003-04-22 | 2010-03-10 | Ipsen Pharma | Conjugués de Camptothecin-Somatostatin |
WO2010087467A1 (fr) | 2009-01-27 | 2010-08-05 | Takeda Pharmaceutical Company Limited | Inhibiteurs de la delta-5-désaturase |
WO2010119992A1 (fr) | 2009-04-16 | 2010-10-21 | Takeda Pharmaceutical Company Limited | Dérivés de n-acyl-n'-phénylpipérazine utiles (notamment) pour la prévention ou le traitement du diabète |
WO2010123047A1 (fr) | 2009-04-24 | 2010-10-28 | 武田薬品工業株式会社 | Cristaux de composé benzoxazinone |
EP2248812A2 (fr) | 2006-06-27 | 2010-11-10 | Takeda Pharmaceutical Company Limited | Composés cycliques condensés comme modulateurs du recepteur GPR40 |
EP2253315A1 (fr) | 2004-03-30 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Dérivés d'acide alkoxypropanoique |
EP2256115A1 (fr) | 2006-11-24 | 2010-12-01 | Takeda Pharmaceutical Company Limited | Composé hétéromonocyclique et ses utilisations |
EP2308839A1 (fr) | 2005-04-20 | 2011-04-13 | Takeda Pharmaceutical Company Limited | Composés hétérocycliques condensés |
US8012931B2 (en) | 2007-03-30 | 2011-09-06 | Ambrx, Inc. | Modified FGF-21 polypeptides and their uses |
EP2385032A1 (fr) | 2002-11-08 | 2011-11-09 | Takeda Pharmaceutical Company Limited | Régulateur de fonction de récepteur GPR40 |
WO2011151782A1 (fr) | 2010-06-02 | 2011-12-08 | Preglem Sa | Rôle de la somatostatine pour moduler l'initiation de la croissance folliculaire dans l'ovaire humain |
WO2012011591A1 (fr) | 2010-07-23 | 2012-01-26 | 武田薬品工業株式会社 | Composé hétérocyclique fusionné et application associée |
US8440720B2 (en) | 2009-09-11 | 2013-05-14 | Influmedix, Inc. | Methods of use of antiviral compounds |
US8557836B2 (en) | 2008-09-16 | 2013-10-15 | The Trustees Of The University Of Pennsylvania | Spiro-piperidine inhibitors |
WO2014007228A1 (fr) | 2012-07-03 | 2014-01-09 | 小野薬品工業株式会社 | Composé ayant une activité agoniste sur un récepteur de la somatostatine, et leur utilisation à des fins médicales |
WO2014030743A1 (fr) | 2012-08-24 | 2014-02-27 | 武田薬品工業株式会社 | Composé hétérocyclique |
US8952128B2 (en) | 2012-11-01 | 2015-02-10 | Ipsen Pharma S.A.S. | Somatostatin-dopamine chimeric analogs |
WO2015046482A1 (fr) | 2013-09-30 | 2015-04-02 | 小野薬品工業株式会社 | Composé ayant une activité agoniste sur les récepteurs de la somatostatine et son utilisation médicale |
US9301950B2 (en) | 2009-08-21 | 2016-04-05 | The Trustees Of The University Of Pennsylvania | Adamantane analogs |
WO2016065326A2 (fr) | 2014-10-24 | 2016-04-28 | Bristol-Myers Squibb Company | Polypeptides fgf-21 modifiés et leurs utilisations |
US9777039B2 (en) | 2012-11-01 | 2017-10-03 | Ipsen Pharma S.A.S. | Somatostatin analogs and dimers thereof |
US9884832B2 (en) | 2011-12-06 | 2018-02-06 | The Trustees Of The University Of Pennsylvania | Inhibitors targeting drug-resistant influenza A |
WO2018147300A1 (fr) | 2017-02-08 | 2018-08-16 | 小野薬品工業株式会社 | Composé ayant une activité agoniste du récepteur de la somatostatine et utilisation pharmaceutique associée |
EP3848353A1 (fr) | 2014-10-24 | 2021-07-14 | Takeda Pharmaceutical Company Limited | Médicaments pour le traitement de maladies ophtalmiques |
-
1998
- 1998-10-28 WO PCT/US1998/022917 patent/WO1999022735A1/fr active Application Filing
- 1998-10-28 AU AU12854/99A patent/AU1285499A/en not_active Abandoned
Non-Patent Citations (2)
Title |
---|
YANG L., ET AL.: "JOURNAL OF MEDICINAL CHEMISTRY.", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 41., no. 13., 1 June 1998 (1998-06-01), US, pages 2175 - 2179., XP002916394, ISSN: 0022-2623, DOI: 10.1021/jm980194h * |
YANG L., ET AL.: "SYNTHESIS AND BIOLOGICAL ACTIVITIES OF POTENT PEPTIDOMIMETICS SELECTIVE FOR SOMATOSTATIN RECEPTOR SUBTYPE 2.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 95., 1 September 1998 (1998-09-01), US, pages 10836 - 10841., XP002916393, ISSN: 0027-8424, DOI: 10.1073/pnas.95.18.10836 * |
Cited By (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003504369A (ja) * | 1999-07-13 | 2003-02-04 | メルク エンド カムパニー インコーポレーテッド | アミドスピロピペリジン類による成長ホルモン放出の促進 |
EP1086947A1 (fr) * | 1999-09-01 | 2001-03-28 | Pfizer Products Inc. | Antagonistes et agonistes de la somatostatin, qui agissent sur le recepteur SST subtype 2 |
US6696418B1 (en) | 1999-09-01 | 2004-02-24 | Pfizer Inc. | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor |
US8110574B2 (en) | 1999-12-14 | 2012-02-07 | Ipsen Pharma S.A.S. | Derivatives of 4-aminopiperidine and their use as a medicament |
FR2802206A1 (fr) * | 1999-12-14 | 2001-06-15 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
WO2001044191A1 (fr) * | 1999-12-14 | 2001-06-21 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
US7115634B2 (en) | 1999-12-14 | 2006-10-03 | Societe De Conseils De Recherches Et D'applications Scientifiques | 4-aminopiperidine and their use as a medicine |
CZ305360B6 (cs) * | 1999-12-14 | 2015-08-19 | Ipsen Pharma, S.A.S. | 4-Aminopiperidinové deriváty, způsob jejich přípravy a použití jako léčiva a farmaceutická kompozice s obsahem těchto derivátů |
US6495589B2 (en) | 2000-04-28 | 2002-12-17 | Pfizer Inc. | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor |
US6316414B1 (en) | 2000-07-31 | 2001-11-13 | Dabur Research Foundation | Somatostatin analogs for the treatment of cancer |
US6720330B2 (en) | 2000-11-17 | 2004-04-13 | Pfizer Inc. | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor |
EP1415986A1 (fr) * | 2001-08-07 | 2004-05-06 | Banyu Pharmaceutical Co., Ltd. | Composes spiro |
US7205417B2 (en) | 2001-08-07 | 2007-04-17 | Banyu Pharmaceutical Co., Ltd. | Spiro compounds |
EP1415986A4 (fr) * | 2001-08-07 | 2005-11-02 | Banyu Pharma Co Ltd | Composes spiro |
AU2002323787B2 (en) * | 2001-08-07 | 2008-04-24 | Banyu Pharmaceutical Co., Ltd. | Spiro compounds |
US7189856B2 (en) | 2001-12-28 | 2007-03-13 | Gideon Shapiro | Non-peptide somatostatin receptor ligands |
EP2385032A1 (fr) | 2002-11-08 | 2011-11-09 | Takeda Pharmaceutical Company Limited | Régulateur de fonction de récepteur GPR40 |
JP2006519200A (ja) * | 2003-02-27 | 2006-08-24 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | シクロアルキル置換アルカン酸誘導体、その製造方法、及び医薬としてのその使用 |
EP2161037A2 (fr) | 2003-04-22 | 2010-03-10 | Ipsen Pharma | Conjugués de Camptothecin-Somatostatin |
EP2662087A1 (fr) | 2003-04-22 | 2013-11-13 | Ipsen Pharma | Vecteurs de somatostatine |
WO2005041962A1 (fr) | 2003-10-31 | 2005-05-12 | Takeda Pharmaceutical Company Limited | Preparation solide comprenant un sensibilisateur a l'insuline, un secretagogue d'insuline et un ester d'acide gras de polyoxyethylene sorbitan |
EP2253315A1 (fr) | 2004-03-30 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Dérivés d'acide alkoxypropanoique |
EP2308839A1 (fr) | 2005-04-20 | 2011-04-13 | Takeda Pharmaceutical Company Limited | Composés hétérocycliques condensés |
WO2006118320A1 (fr) | 2005-04-28 | 2006-11-09 | Takeda Pharmaceutical Company Limited | Composé de thiénopyrimidone |
WO2006132440A1 (fr) | 2005-06-09 | 2006-12-14 | Takeda Pharmaceutical Company Limited | Preparation solide |
WO2007028135A2 (fr) | 2005-09-01 | 2007-03-08 | Takeda Pharmaceutical Company Limited | Composes a base d'imidazopyridine |
US8158791B2 (en) | 2005-11-10 | 2012-04-17 | Msd K.K. | Aza-substituted spiro derivatives |
WO2007055418A1 (fr) | 2005-11-10 | 2007-05-18 | Banyu Pharmaceutical Co., Ltd. | Derive spiro aza-substitue |
WO2007074884A1 (fr) | 2005-12-28 | 2007-07-05 | Takeda Pharmaceutical Company Limited | Agent thérapeutique pour traiter le diabète |
EP2743268A2 (fr) | 2006-06-27 | 2014-06-18 | Takeda Pharmaceutical Company Limited | Composés cycliques condensés comme modulateurs du recepteur GPR40 |
EP2431367A2 (fr) | 2006-06-27 | 2012-03-21 | Takeda Pharmaceutical Company Limited | Composés cycliques condensés comme modulateurs du recepteur GPR40 |
EP2248812A2 (fr) | 2006-06-27 | 2010-11-10 | Takeda Pharmaceutical Company Limited | Composés cycliques condensés comme modulateurs du recepteur GPR40 |
WO2008016131A1 (fr) | 2006-08-04 | 2008-02-07 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique à cycles fusionnés |
EP2256115A1 (fr) | 2006-11-24 | 2010-12-01 | Takeda Pharmaceutical Company Limited | Composé hétéromonocyclique et ses utilisations |
US8012931B2 (en) | 2007-03-30 | 2011-09-06 | Ambrx, Inc. | Modified FGF-21 polypeptides and their uses |
US8383365B2 (en) | 2007-03-30 | 2013-02-26 | Ambrx, Inc. | Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine derivatives |
US9079971B2 (en) | 2007-03-30 | 2015-07-14 | Ambrx, Inc. | Modified FGF-21 polypeptides comprising non-naturally occurring amino acids |
US9517273B2 (en) | 2007-03-30 | 2016-12-13 | Ambrx, Inc. | Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids |
US10961291B2 (en) | 2007-03-30 | 2021-03-30 | Ambrx, Inc. | Modified FGF-21 polypeptides and their uses |
US10377805B2 (en) | 2007-03-30 | 2019-08-13 | Ambrx, Inc. | Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses |
US9975936B2 (en) | 2007-03-30 | 2018-05-22 | Ambrx, Inc. | Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids |
WO2008136428A1 (fr) | 2007-04-27 | 2008-11-13 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique à cinq chaînons à teneur en azote |
EP2253630A1 (fr) | 2007-05-21 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique et son utilisation |
WO2008143262A1 (fr) | 2007-05-21 | 2008-11-27 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique et son utilisation |
WO2009008487A1 (fr) | 2007-07-12 | 2009-01-15 | Takeda Pharmaceutical Company Limited | Préparation enrobée |
WO2009123316A1 (fr) | 2008-04-04 | 2009-10-08 | 武田薬品工業株式会社 | Dérivé hétérocyclique et son utilisation |
WO2009128481A1 (fr) | 2008-04-16 | 2009-10-22 | 武田薬品工業株式会社 | Composé hétérocyclique azoté à cinq chaînons |
WO2010016552A1 (fr) | 2008-08-07 | 2010-02-11 | 武田薬品工業株式会社 | Agent thérapeutique pour le syndrome du côlon irritable |
US8557836B2 (en) | 2008-09-16 | 2013-10-15 | The Trustees Of The University Of Pennsylvania | Spiro-piperidine inhibitors |
US9464075B2 (en) | 2008-09-16 | 2016-10-11 | The Trustees Of The University Of Pennsylvania | Influenza A virus inhibition |
US9453005B2 (en) | 2008-09-16 | 2016-09-27 | The Trustees Of The University Of Pennsylvania | Inhibition of influenza M2 proton channel |
WO2010087467A1 (fr) | 2009-01-27 | 2010-08-05 | Takeda Pharmaceutical Company Limited | Inhibiteurs de la delta-5-désaturase |
WO2010119992A1 (fr) | 2009-04-16 | 2010-10-21 | Takeda Pharmaceutical Company Limited | Dérivés de n-acyl-n'-phénylpipérazine utiles (notamment) pour la prévention ou le traitement du diabète |
WO2010123047A1 (fr) | 2009-04-24 | 2010-10-28 | 武田薬品工業株式会社 | Cristaux de composé benzoxazinone |
US9301950B2 (en) | 2009-08-21 | 2016-04-05 | The Trustees Of The University Of Pennsylvania | Adamantane analogs |
US8440720B2 (en) | 2009-09-11 | 2013-05-14 | Influmedix, Inc. | Methods of use of antiviral compounds |
WO2011151782A1 (fr) | 2010-06-02 | 2011-12-08 | Preglem Sa | Rôle de la somatostatine pour moduler l'initiation de la croissance folliculaire dans l'ovaire humain |
WO2012011591A1 (fr) | 2010-07-23 | 2012-01-26 | 武田薬品工業株式会社 | Composé hétérocyclique fusionné et application associée |
US9884832B2 (en) | 2011-12-06 | 2018-02-06 | The Trustees Of The University Of Pennsylvania | Inhibitors targeting drug-resistant influenza A |
WO2014007228A1 (fr) | 2012-07-03 | 2014-01-09 | 小野薬品工業株式会社 | Composé ayant une activité agoniste sur un récepteur de la somatostatine, et leur utilisation à des fins médicales |
WO2014030743A1 (fr) | 2012-08-24 | 2014-02-27 | 武田薬品工業株式会社 | Composé hétérocyclique |
US8952128B2 (en) | 2012-11-01 | 2015-02-10 | Ipsen Pharma S.A.S. | Somatostatin-dopamine chimeric analogs |
US9603942B2 (en) | 2012-11-01 | 2017-03-28 | Ipsen Pharma S.A.S. | Somatostatin-dopamine chimeric analogs |
US9731027B2 (en) | 2012-11-01 | 2017-08-15 | Ipsen Pharma S.A.S. | Somatostatin-dopamine chimeric analogs |
US9777039B2 (en) | 2012-11-01 | 2017-10-03 | Ipsen Pharma S.A.S. | Somatostatin analogs and dimers thereof |
RU2666352C2 (ru) * | 2013-09-30 | 2018-09-07 | Оно Фармасьютикал Ко., Лтд. | Соединение с агонистической активностью в отношении рецепторов соматостатина и его фармацевтическое применение |
WO2015046482A1 (fr) | 2013-09-30 | 2015-04-02 | 小野薬品工業株式会社 | Composé ayant une activité agoniste sur les récepteurs de la somatostatine et son utilisation médicale |
WO2016065326A2 (fr) | 2014-10-24 | 2016-04-28 | Bristol-Myers Squibb Company | Polypeptides fgf-21 modifiés et leurs utilisations |
US9631004B2 (en) | 2014-10-24 | 2017-04-25 | Bristol-Myers Squibb Company | Modified FGF-21 polypeptides comprising an internal deletion and uses thereof |
EP3412302A1 (fr) | 2014-10-24 | 2018-12-12 | Bristol-Myers Squibb Company | Polypeptides fgf-21 modifiées et leurs utilisations |
US10189883B2 (en) | 2014-10-24 | 2019-01-29 | Bristol-Myers Squibb Company | Therapeutic uses of modified FGF-21 polypeptides |
US10377806B2 (en) | 2014-10-24 | 2019-08-13 | Bristol-Myers Squibb Company | Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof |
US9434778B2 (en) | 2014-10-24 | 2016-09-06 | Bristol-Myers Squibb Company | Modified FGF-21 polypeptides comprising an internal deletion and uses thereof |
EP3848353A1 (fr) | 2014-10-24 | 2021-07-14 | Takeda Pharmaceutical Company Limited | Médicaments pour le traitement de maladies ophtalmiques |
EP3909596A1 (fr) | 2014-10-24 | 2021-11-17 | Bristol-Myers Squibb Company | Polypeptides fgf-21 modifiées et leurs utilisations |
US11248031B2 (en) | 2014-10-24 | 2022-02-15 | Bristol-Myers Squibb Company | Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides |
WO2018147300A1 (fr) | 2017-02-08 | 2018-08-16 | 小野薬品工業株式会社 | Composé ayant une activité agoniste du récepteur de la somatostatine et utilisation pharmaceutique associée |
Also Published As
Publication number | Publication date |
---|---|
AU1285499A (en) | 1999-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999022735A1 (fr) | Agonistes de la somatostatine | |
US6057338A (en) | Somatostatin agonists | |
US6063796A (en) | Somatostatin agonists | |
US6025372A (en) | Somatostatin agonists | |
US6423725B1 (en) | 4-(2-keto-1-benzimidazolinyl)piperidine compounds as ORL1-receptor agonists | |
US6552043B1 (en) | Benzimidazolinyl piperidines as CGRP ligands | |
CA2430978C (fr) | Inhibiteurs de vla-4 | |
US8044080B2 (en) | Isoxazoline derivative and novel process for its preparation | |
JP2019518036A (ja) | Apjアゴニストとしての6−ヒドロキシ−5−(フェニル/ヘテロアリールスルホニル)ピリミジン−4(1h)−オン | |
JP2018538304A (ja) | Apj受容体のapjアゴニストとしてのヘテロアリールヒドロキシピリミジノン | |
JP2008510006A (ja) | 化合物 | |
JP2002503207A (ja) | Xa因子阻害剤としてのN―(アミジノフェニル)―N’―(置換)―3H―2,4―ベンゾジアゼピン―3―オン誘導体 | |
JP2006501236A (ja) | ムスカリン性レセプター拮抗薬としてのフルオロおよびスルホニルアミノ含有3,6−二置換アザビシクロ(3.1.0)ヘキサン誘導体 | |
CA2681861A1 (fr) | Derive de l'ornithine | |
US6117880A (en) | Somatostatin agonists | |
US6387932B1 (en) | Somatostatin agonists | |
US7189856B2 (en) | Non-peptide somatostatin receptor ligands | |
NO178188B (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive 4,5,6,7-tetrahydro-benzimidazolderivater | |
WO1997005129A1 (fr) | (r)-5-bromo-n-(1-ethyl-4-methylhexahydro-1h-1,4-diazepin-6-yl)-2-methoxy-6-methylamino-3-pyridine-carboxamide, son procede d'obtention et medicament le contenant | |
CZ62494A3 (en) | Hetero-tricyclically substituted derivatives of phenyl-cyclohexanecarboxylic acid, process of their preparation, medicaments in which they are comprised, process for preparing such medicaments and their use | |
CN111372928B (zh) | 用作钾通道抑制剂的苯并咪唑衍生物 | |
CZ117393A3 (en) | Imidazolyl-substituted cyclohexane derivatives | |
EP1765809B1 (fr) | Derives de xanthine utilises en tant qu'antagonistes du recepteur muscarinique | |
US6780863B1 (en) | Bis-basic compounds with tryptase-inhibitory activity | |
EP4303215A1 (fr) | Agoniste du récepteur glp-1, composition pharmaceutique le comprenant et son procédé de préparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GD GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: KR |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |